Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soon Thye Lim

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
Cancer Cell|January 11, 2017
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKTJuliane Paul, Maurice Soujon, Antje M Wengner, et al.
Pharmacotherapy|February 6, 2021
Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximabChia Jie Tan, Rajneesh Kumar, Narendran Koomanan, et al.
Scientific Reports|March 11, 2020
A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab EraRyan Mao Heng Lim, Natalie Pei Xin Chan, Lay Poh Khoo, et al.
Leukemia & Lymphoma|January 19, 2018
The impact of time from diagnosis to treatment in diffuse large B-cell lymphomaColin Phipps, Yuh Shan Lee, Hao Ying, et al.
Leukemia & Lymphoma|May 24, 2011
Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer/T-cell lymphomaWilliam Y K Hwang, Liang Piu Koh, Soon-Thye Lim, et al.
Leukemia & Lymphoma|February 26, 2008
Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximabLynette Ngo, Siew-Wan Hee, Lay-Cheng Lim, et al.
European Journal of Haematology|November 22, 2007
Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosisSoon Thye Lim, Siew Wan Hee, Richard Quek, et al.
Frontiers in Immunology|April 29, 2024
Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphomaWendy W L Lee, Jing Quan Lim, Tiffany P L Tang, et al.
Cancers|April 12, 2022
A Prognostic Model Using Post-Steroid Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Primary Central Nervous System LymphomaYu Tung Lo, Vivian Yujing Lim, Melissa Ng, et al.
Hematology Reports|February 22, 2023
Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin's LymphomaGrace Fangmin Tan, Siting Goh, Esther Wei Yin Chang, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
Cancer Cell|January 11, 2017
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKTJuliane Paul, Maurice Soujon, Antje M Wengner, et al.
Pharmacotherapy|February 6, 2021
Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximabChia Jie Tan, Rajneesh Kumar, Narendran Koomanan, et al.
Scientific Reports|March 11, 2020
A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab EraRyan Mao Heng Lim, Natalie Pei Xin Chan, Lay Poh Khoo, et al.
Leukemia & Lymphoma|January 19, 2018
The impact of time from diagnosis to treatment in diffuse large B-cell lymphomaColin Phipps, Yuh Shan Lee, Hao Ying, et al.
Leukemia & Lymphoma|May 24, 2011
Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer/T-cell lymphomaWilliam Y K Hwang, Liang Piu Koh, Soon-Thye Lim, et al.
Leukemia & Lymphoma|February 26, 2008
Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximabLynette Ngo, Siew-Wan Hee, Lay-Cheng Lim, et al.
European Journal of Haematology|November 22, 2007
Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosisSoon Thye Lim, Siew Wan Hee, Richard Quek, et al.
Frontiers in Immunology|April 29, 2024
Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphomaWendy W L Lee, Jing Quan Lim, Tiffany P L Tang, et al.
Cancers|April 12, 2022
A Prognostic Model Using Post-Steroid Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Primary Central Nervous System LymphomaYu Tung Lo, Vivian Yujing Lim, Melissa Ng, et al.
Hematology Reports|February 22, 2023
Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin's LymphomaGrace Fangmin Tan, Siting Goh, Esther Wei Yin Chang, et al.
Pageof 19